Platform Technologies to Discover
Novel Antibody Therapeutics

Our journey of discovering novel antibody therapeutics began back in 2007. Initially, the company focused on creating and validating its 1011 diverse phage display human antibody library, Ymax®-ABL. Having established itself as an antibody and novel biologics expert through successful discovery partnerships recently have developed its proprietary bi-specific antibody platform technology ALiCE to additionally discover & develop bi-specific antibodies.
Novel Bi-specific Antibody Platform Technology
ALiCE: Antibody Like Cell Engager with potential to create numerous block-buster bi-specific antibodies.
Proprietary Human Antibody Library
Phage display human antibody library with 1011 diversity.